TG Therapeutics (TGTX, $10.40) gets FDA nod on RMS-treating antibody
The U.S. Food and Drug Administration (FDA) approved TG Therapeutics Inc's Briumvi – a monoclonal antibody for treating patients with relapsing forms of multiple sclerosis (RMS). Briumvi is the first and only anti-CD20 monoclonal antibody approved for RMS that can be administered in a one-hour infusion following the first dose.
The approval by the FDA may help offset the headwind to the company's finances from the withdrawal of its lymphatic cancer drug earlier this year. The approval was based on a late-stage study that suggested that the drug was effective in mitigating the annualized relapse rates in patients. It, however, comes with a caution of infusion reactions from the drug.
TG expects to launch Briumvi commercially in the U.S. in the first quarter of 2023.
TGTX in +5.18% Uptrend, rising for three consecutive days on June 18, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where TGTX advanced for three days, in of 303 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 03, 2026. You may want to consider a long position or call options on TGTX as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for TGTX just turned positive on June 09, 2026. Looking at past instances where TGTX's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 198 cases where TGTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TGTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
TGTX broke above its upper Bollinger Band on June 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TGTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TGTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.947) is normal, around the industry mean (20.059). P/E Ratio (18.587) is within average values for comparable stocks, (35.871). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.677). TGTX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (12.195) is also within normal values, averaging (361.315).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company
Industry Biotechnology
Advertisement